Evidence map›Paper›PMID 34298641›Full record

ArticleCancers2021

MOUSSE: Multi-Omics Using Subject-Specific SignaturEs.

Giuseppe Fiorentino, Roberto Visintainer, Enrico Domenici, Mario Lauria, Luca Marchetti

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giuseppe FiorentinoFondazione The Microsoft Research, University of Trento Centre for Computational and Systems Biology (COSBI), 38068 Rovereto, Italy.ORCID 0000-0001-9513-608X
Roberto VisintainerFondazione The Microsoft Research, University of Trento Centre for Computational and Systems Biology (COSBI), 38068 Rovereto, Italy.
Enrico DomeniciFondazione The Microsoft Research, University of Trento Centre for Computational and Systems Biology (COSBI), 38068 Rovereto, Italy.ORCID 0000-0001-7436-6919
Mario LauriaFondazione The Microsoft Research, University of Trento Centre for Computational and Systems Biology (COSBI), 38068 Rovereto, Italy.ORCID 0000-0001-5983-7292
Luca MarchettiFondazione The Microsoft Research, University of Trento Centre for Computational and Systems Biology (COSBI), 38068 Rovereto, Italy.ORCID 0000-0001-9043-7705

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-throughput technologies make it possible to produce a large amount of data representing different biological layers, examples of which are genomics, proteomics, metabolomics and transcriptomics. Omics data have been individually investigated to understand the molecular bases of various diseases, but this may not be sufficient to fully capture the molecular mechanisms and the multilayer regulatory processes underlying complex diseases, especially cancer. To overcome this problem, several multi-omics integration methods have been introduced but a commonly agreed standard of analysis is still lacking. In this paper, we present MOUSSE, a novel normalization-free pipeline for unsupervised multi-omics integration. The main innovations are the use of rank-based subject-specific signatures and the use of such signatures to derive subject similarity networks. A separate similarity network was derived for each omics, and the resulting networks were then carefully merged in a way that considered their informative content. We applied it to analyze survival in ten different types of cancer. We produced a meaningful clusterization of the subjects and obtained a higher average classification score than ten state-of-the-art algorithms tested on the same data. As further validation, we extracted from the subject-specific signatures a list of relevant features used for the clusterization and investigated their biological role in survival. We were able to verify that, according to the literature, these features are highly involved in cancer progression and differential survival.

Indexed as

biomarker identificationcancermulti-omics data integrationprecision medicineunsupervised clustering

Identifiers

PMID34298641
PMCPMC8304726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.